Nurix Therapeutics Stock Performance
| NRIX Stock | USD 21.82 0.23 1.04% |
The company secures a Beta (Market Risk) of 1.89, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nurix Therapeutics will likely underperform. At this point, Nurix Therapeutics has a negative expected return of -0.16%. Please make sure to verify Nurix Therapeutics' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and relative strength index , to decide if Nurix Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nurix Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's forward indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (3.90) | Five Day Return (6.11) | Year To Date Return 107.34 | Ten Year Return 11.47 | All Time Return 11.47 |
1 | Disposition of 200 shares by Christine Ring of Nurix Therapeutics at 25.62 subject to Rule 16b-3 | 09/03/2024 |
2 | Renaissance Technologies LLC Purchases 144,700 Shares of Nurix Therapeutics, Inc. - MarketBeat | 09/26/2024 |
3 | Disposition of 300 shares by Christine Ring of Nurix Therapeutics at 22.81 subject to Rule 16b-3 | 10/01/2024 |
4 | Nurix Therapeutics Given New 26.00 Price Target at Royal Bank of Canada | 10/15/2024 |
5 | Acquisition by Kunkel Lori Anne of 25000 shares of Nurix Therapeutics at 16.19 subject to Rule 16b-3 | 10/18/2024 |
6 | Nurix Therapeutics Announces Presentations atthe 7th Annual TPD Induced Proximity Summit | 10/21/2024 |
7 | Disposition of 1924 shares by Christine Ring of Nurix Therapeutics subject to Rule 16b-3 | 10/30/2024 |
8 | Nurix therapeutics CFO Hans van Houte sells 57,554 in stock | 10/31/2024 |
9 | Nurix therapeutics CFO Hans van Houte sells 86,083 in stock | 11/01/2024 |
10 | Disposition of 3290 shares by Christine Ring of Nurix Therapeutics at 25.0 subject to Rule 16b-3 | 11/04/2024 |
11 | Subdued Growth No Barrier To Nurix Therapeutics, Inc. With Shares Advancing 25 | 11/07/2024 |
12 | Redmile Group, LLC Adjusts Stake in Krystal Biotech Inc | 11/15/2024 |
13 | Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leu... | 11/20/2024 |
| Begin Period Cash Flow | 65.4 M |
Nurix |
Nurix Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,509 in Nurix Therapeutics on August 28, 2024 and sell it today you would lose (327.00) from holding Nurix Therapeutics or give up 13.03% of portfolio value over 90 days. Nurix Therapeutics is currently does not generate positive expected returns and assumes 3.4402% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Nurix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nurix Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nurix Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nurix Therapeutics, and traders can use it to determine the average amount a Nurix Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.047
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NRIX |
Estimated Market Risk
| 3.44 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nurix Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nurix Therapeutics by adding Nurix Therapeutics to a well-diversified portfolio.
Nurix Therapeutics Fundamentals Growth
Nurix Stock prices reflect investors' perceptions of the future prospects and financial health of Nurix Therapeutics, and Nurix Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nurix Stock performance.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (4.34) % | ||||
| Current Valuation | 1.14 B | ||||
| Shares Outstanding | 70.84 M | ||||
| Price To Book | 4.14 X | ||||
| Price To Sales | 27.68 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | (145.87 M) | ||||
| EBITDA | (141.41 M) | ||||
| Net Income | (143.95 M) | ||||
| Cash And Equivalents | 344.48 M | ||||
| Cash Per Share | 7.31 X | ||||
| Total Debt | 30.61 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.26 X | ||||
| Book Value Per Share | 5.62 X | ||||
| Cash Flow From Operations | (81.36 M) | ||||
| Earnings Per Share | (2.90) X | ||||
| Market Capitalization | 1.56 B | ||||
| Total Asset | 355.6 M | ||||
| Retained Earnings | (545.2 M) | ||||
| Working Capital | 208.54 M | ||||
About Nurix Therapeutics Performance
Evaluating Nurix Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Nurix Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nurix Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (42.72) | (40.58) | |
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.83) | (0.78) |
Things to note about Nurix Therapeutics performance evaluation
Checking the ongoing alerts about Nurix Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nurix Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nurix Therapeutics generated a negative expected return over the last 90 days | |
| Nurix Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (143.95 M) with loss before overhead, payroll, taxes, and interest of (145.87 M). | |
| Nurix Therapeutics currently holds about 344.48 M in cash with (81.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia |
- Analyzing Nurix Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nurix Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Nurix Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nurix Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nurix Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nurix Therapeutics' stock. These opinions can provide insight into Nurix Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.